排除儿童代谢相关脂肪性肝病显著肝纤维化的pFIB评分开发与验证
在327名重度肥胖儿童和青少年前瞻性队列中,基于性别、种族、体重z评分、胰岛素抵抗指数、ALT和高血压建立连续(pFIB-c)和简化(pFIB-6)评分以排除显著(≥F2)纤维化,并在弹性成像(n=504)和多组活检证实MASLD(n=261)队列中验证;pFIB-c和pFIB-6的c-statistic分别为0.839和0.826,优于现有指标,推导和弹性成像验证队列阴性预测值均>90%。
要点
- pFIB-c和pFIB-6评分用于排除儿童MASLD相关显著肝纤维化(≥F2)。
- 推导队列和弹性成像验证队列中两评分阴性预测值均>90%。
- 在三级转诊中心高纤维化患病率和高ALT人群中评分准确性较低。
核心结论
- 在总计约1100名儿童和青少年的多个队列中开发了纳入易得临床变量的新型风险评分,用于排除儿童MASLD相关纤维化。
- 评分在非选择性肥胖儿童和青少年队列中表现优于转诊至三级肝病中心的患者。
研究设计与样本
- 前瞻性队列纳入327名重度肥胖儿童和青少年,以瞬时弹性成像评估肝纤维化。
- 采用逻辑回归建立连续(pFIB-c)和简化(pFIB-6)诊断评分,并与现有无创纤维化评分比较。
- 评分在弹性成像队列(n=504)和多组活检证实MASLD队列(n=261)中验证。
主要发现
- pFIB-c和pFIB-6的c-statistic分别为0.839和0.826,优于现有指标。
- 推导队列和弹性成像验证队列中两评分阴性预测值均>90%。
- 组织学队列中pFIB-c的AUROC在0.710至0.770之间。
- 评分应用于三级转诊中心(显著纤维化患病率高、ALT水平高)人群时准确性较低。
关键数值与推荐
- pFIB-c和pFIB-6评分纳入患者性别、种族、体重z评分、稳态模型胰岛素抵抗指数、ALT和高血压。
- 评分目标为排除显著(≥F2)纤维化,推导和弹性成像验证队列阴性预测值>90%。
- 组织学队列中pFIB-c的AUROC在0.710至0.770之间。
临床怎么用
- 原文未据此给出推荐。
局限性
- 评分应用于三级转诊中心人群时准确性较低,这些人群显著纤维化患病率高且ALT水平高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent pediatric liver disease, yet accurate risk scores for referral of children/adolescents with suspected clinically significant liver fibrosis are currently lacking. APPROACH AND RESULTS: Clinical and biochemical variables were collected in a prospective cohort of 327 children and adolescents with severe obesity, in whom liver fibrosis was evaluated by transient elastography. Logistic regression was performed to establish continuous (pFIB-c) and simplified (pFIB-6) diagnostic scores that accurately exclude significant (≥F2) fibrosis. Performance for each was compared to established noninvve fibrosis scores. These scores were validated in elastography (n=504) and multiple biopsy-proven MASLD (n=261) cohorts. Patient sex, ethnicity, weight z-score, homeostatic model assessment of insulin resistance index, ALT, and presence of hypertension were included in the scores. The pFIB-c and pFIB-6 exhibited good discriminatory capacity (c-statistic of 0.839 and 0.826), outperforming existing indices. Negative predictive values were >90% for both scores in the derivation and elastography validation cohorts. Performance in the histological cohorts varied (AUROCs for the pFIB-c between 0.710 and 0.770), as the scores were less accurate when applied to populations in tertiary referral centers characterized by a high prevalence of significant fibrosis and high ALT levels. CONCLUSIONS: Analyzing several cohorts totaling approximately 1100 children and adolescents, we developed novel risk scores incorporating readily available clinical variables. In accordance with the aim of excluding pediatric MASLD-associated fibrosis, the scores performed better in nonselected cohorts of children and adolescents living with obesity than in patients referred to tertiary liver units.
引用
- Lefere S, Mosca A, Hudert C, et al. Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD. Hepatology. 2024. PMID: 39028885. doi:10.1097/HEP.0000000000001016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。